A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed or Refractory Hodgkins Lymphoma
Latest Information Update: 09 Aug 2022
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms Nivo40
- 17 Jun 2022 Results assessing the comparison of efficacy of Nivolumab 40 Mg expanded prospective cohort with the retrospective group of patients treated with Nivo 3 mg/kg presented at the 27th Congress of the European Haematology Association.
- 08 Dec 2020 Results assessing efficacy and safety of nivolumab 40 mg in relapsed or refractory Classical Hodgkin Lymphoma, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 21 Jun 2020 Results (N=9) of NCT03343665 and NCT03259529 assessing Overall response rate of Immunotherapy with Nivolumab in Patients with Relapsed/Refractory Hiv-Related Lymphomas, presented at the 25th Congress of the European Haematology Association